Related references
Note: Only part of the references are listed.Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
Elisa Fabbrini et al.
HEPATOLOGY (2010)
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
Maartje E. Visser et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
Fatima Akdim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2 '-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Rosie Z. Yu et al.
CLINICAL PHARMACOKINETICS (2009)
Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety
Runhua Hou et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2009)
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice
Esther Merki et al.
CIRCULATION (2008)
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
David Preiss et al.
CLINICAL SCIENCE (2008)
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
Frederick F. Samaha et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Marina Cuchel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
Statin safety: A systematic review
M Law et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia
RR Sankatsing et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Lipoprotein(a) An elusive cardiovascular risk factor
L Berglund et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Progress in antisense technology
ST Crooke
ANNUAL REVIEW OF MEDICINE (2004)
Fatty liver in familial hypobetalipoproteinemia:: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity
T Tanoli et al.
JOURNAL OF LIPID RESEARCH (2004)
CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
CE Chandler et al.
JOURNAL OF LIPID RESEARCH (2003)
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
DJ Rader et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Antisense technologies - Improvement through novel chemical modifications
J Kurreck
EUROPEAN JOURNAL OF BIOCHEMISTRY (2003)
Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis
G Schonfeld et al.
JOURNAL OF LIPID RESEARCH (2003)
Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins
TC Andrews et al.
AMERICAN JOURNAL OF MEDICINE (2001)
Share Paper
